Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen.
Per the consensus of Wall Street analysts, Compass Pathways (NASDAQ: CMPS) stock is on track for an absolutely stellar 12 months. They see its shares rising by 307% compared to where it is today. For reference, a typical year sees the stock market rise by around 10%, so the bean counters are doubtlessly calculating that the upstart biotech will succeed in its ambitions to commercialize its first psychedelic therapy.
Unlike many frothy estimates, there's actually a credible path for Compass to wow the market to the extent that the analysts anticipate, though the outcome is very far from being assured. Here's what needs to happen.
Some of the most important upcoming catalysts for Compass' stock have little to do with its own research and development (R&D) or business development activities.
Source Fool.com
